News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Prof. Dr. Bernhard Scholkopf, Max Plank Director, Named To Health Discovery Corporation (DWCM.OB) Scientific Advisory Board

10/19/2005 5:10:22 PM

WACO, Texas, Nov. 6 /PRNewswire-FirstCall/ -- Health Discovery Corporation (BULLETIN BOARD: HDVY) , formerly Direct Wireless Communications, Inc. (BULLETIN BOARD: DWCM) , a biotechnology company which is focused on biomarker and pathway discovery for diagnostic markers and drug targets today announced the appointment of Prof. Dr. Bernhard Scholkopf to its Scientific Advisory Board.

Prof. Dr. Scholkopf is a Director at the Max Plank Institute for Biological Cybernetics in Tubingen, Germany and an elected member of the Max Plank Society. He was recently appointed Honorarprofessor for machine learning at the Technical University in Berlin and has taught at the Humboldt University and the Technical University in Berlin.

Prof. Dr. Scholkopf won the prize for best scientific project at the German National Research Center for Computer Science (GMD) and his thesis on Support Vector Learning won the annual dissertation prize of the German Association for Computer Science (GI). Prof. Dr. Scholkolf is a former research scientist at AT&T Bell Labs, GMD - FIRST in Germany, the Australian National University, and Microsoft Research in the United Kingdom. Prof. Dr. Scholkolf has authored numerous publications, as well as, Chaired and presented his research at a number of prestigious international scientific meetings

Prof. Dr. Scholkopf received a M.Sc. in mathematics and the Lionel Cooper Memorial Prize from the University of London in London, England. He then received a Diploma in Physics from the Eberhard-Karls-Universitat in Tubingen, Germany and obtained a doctorate in computer science from the Technical University in Berlin, Germany.

"It is truly an honor to have Prof. Dr. Scholkolf, with his tremendous academic background, scientific accomplishments and expertise in computational biology, agree to become a member of our Scientific Advisory Board," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "We look forward to working with Dr. Scholkolf as we progress to the forefront of biomarker and pathway discovery."

Prof. Dr. Scholkolf commented, "I believe that in the years to come, medicine will strongly benefit from machine learning and other branches of advanced information technology. I am excited about this prospect, with Dr. Barnhill, and look forward to applying my work in this field."

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

This release was issued on behalf of the above organization by Send2Press(TM), a unit of Neotrope(R).

Health Discovery Corporation

CONTACT: Robert S. Braswell IV of Health Discovery Corporation,+1-512-583-4500,

Read at

comments powered by Disqus